Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Westin

Showing results (1-10 of 98) with videos related to

Pageof 10
Sort By:
Blood|March 31, 2022
Always be prepared for successJason Westin
Blood|September 28, 2019
Ibrutinib and lenalidomide: when 1+1 = >2Jason Westin
Blood|April 3, 2025
Two strikes, base hit: odronextamab after CAR T cells in LBCLJason Westin
Journal of Comparative Effectiveness Research|November 19, 2013
R-CHOP every 21 days for diffuse large B-cell lymphoma: still the standard of care?Jason Westin, Fredrick Hagemeister
Leukemia & Lymphoma|October 30, 2009
De novo CD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapyJason Westin, Peter McLaughlin
Advances in Experimental Medicine and Biology|April 18, 2020
CAR T-CellsRanjit Nair, Jason Westin
Advances in Experimental Medicine and Biology|January 1, 2022
CAR T CellsRanjit Nair, Jason Westin
International Journal of Cancer|September 25, 2024
The future of immunotherapy for diffuse large B-cell lymphomaJohannes Duell, Jason Westin
Current Oncology Reports|October 20, 2023
Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell LymphomaAnath C Lionel, Jason Westin
Blood|March 3, 2022
CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?Jason Westin, Laurie H Sehn
Pageof 10

Showing results (1-10 of 98) with videos related to

Sort By:
Pageof 10
Blood|March 31, 2022
Always be prepared for successJason Westin
Blood|September 28, 2019
Ibrutinib and lenalidomide: when 1+1 = >2Jason Westin
Blood|April 3, 2025
Two strikes, base hit: odronextamab after CAR T cells in LBCLJason Westin
Journal of Comparative Effectiveness Research|November 19, 2013
R-CHOP every 21 days for diffuse large B-cell lymphoma: still the standard of care?Jason Westin, Fredrick Hagemeister
Leukemia & Lymphoma|October 30, 2009
De novo CD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapyJason Westin, Peter McLaughlin
Advances in Experimental Medicine and Biology|April 18, 2020
CAR T-CellsRanjit Nair, Jason Westin
Advances in Experimental Medicine and Biology|January 1, 2022
CAR T CellsRanjit Nair, Jason Westin
International Journal of Cancer|September 25, 2024
The future of immunotherapy for diffuse large B-cell lymphomaJohannes Duell, Jason Westin
Current Oncology Reports|October 20, 2023
Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell LymphomaAnath C Lionel, Jason Westin
Blood|March 3, 2022
CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?Jason Westin, Laurie H Sehn
Pageof 10